Rare Disease : Episode 1

Video

Episode 1 - Recognizing Rare Diseases in the United States

In a peer exchange moderated by Dr. Peter Salgo, Hugh Fatodu and Drs. Patrick F. Fogarty, Maria Lopes, and Michelle Petri share their insights on the evolving dynamics of rare diseases in contemporary healthcare and managed care, and specifically address the implications for hemophilia and systemic lupus erythematosus (SLE). In the US, a rare disease is defined as a condition that affects than 200,000 persons. However, despite the 25 million American lives currently affected by more than 7,000 identified rare diseases, the patient and provider communities are still plagued by a general lack of awareness, a high risk for misdiagnosis, and a scarcity of treatment options. There is an acknowledgement among the panelists that the early recognition of diseases such as hemophilia and SLE has “very significant” implications for therapy, perhaps life-changing and even life-saving.


Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Videos
David Awad, PharmD, BCOP
Merrill H. Stewart, MD
Andrew Evens, DO, MBA, MSc, deputy director for clinical services and chief physician officer, Rutgers Cancer Institute and Jack & Sheryl Morris Cancer Center
David Awad, PharmD, BCOP
Coral Omene, MD, PhD, sitting for a vieo interview
Constance Blunt, MD, medical oncologist, Mary Bird Perkins Cancer Center
Merrill H. Stewart, MD
Coral Omene, MD, PhD, sitting for a vieo interview
David Awad, PharmD, BCOP
Related Content
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo